期刊文献+

Transactivating-transduction protein-polyethylene glycol modified liposomes traverse the blood-spinal cord and blood-brain barriers 被引量:1

Transactivating-transduction protein-polyethylene glycol modified liposomes traverse the blood-spinal cord and blood-brain barriers
下载PDF
导出
摘要 Naive liposomes can cross the blood-brain barrier and blood-spinal cord barrier in small amounts. Liposomes modified by a transactivating-transduction protein can deliver antibiotics for the treatment of acute bacterial infection-induced brain inflammation. Liposomes conjugated with polyethylene glycol have the capability of long-term circulation. In this study we prepared transactivating-transduction protein-polyethylene glycol-modified liposomes labeled with fiuorescein isothiocyanate. Thus, liposomes were characterized by transmembrane, long-term circulation and fluorescence tracing. Uptake, cytotoxicity, and the ability of traversing blood-spinal cord and blood-brain barriers were observed following coculture with human breast adenocarcinoma cells (MCF-7). Results demonstrated that the liposomes had good biocompatibility, and low cytotoxicity when cocultured with human breast adenocarcinoma cells. Liposomes could traverse cell membranes and entered the central nervous system and neurocytes through the blood-spinal cord and blood-brain barriers of rats via the systemic circulation. These results verified that fluorescein isothiocyanate-modified transactivating-transduction protein-polyethylene glycol liposomes have the ability to traverse the blood-spinal cord and blood-brain barriers. Naive liposomes can cross the blood-brain barrier and blood-spinal cord barrier in small amounts. Liposomes modified by a transactivating-transduction protein can deliver antibiotics for the treatment of acute bacterial infection-induced brain inflammation. Liposomes conjugated with polyethylene glycol have the capability of long-term circulation. In this study we prepared transactivating-transduction protein-polyethylene glycol-modified liposomes labeled with fiuorescein isothiocyanate. Thus, liposomes were characterized by transmembrane, long-term circulation and fluorescence tracing. Uptake, cytotoxicity, and the ability of traversing blood-spinal cord and blood-brain barriers were observed following coculture with human breast adenocarcinoma cells (MCF-7). Results demonstrated that the liposomes had good biocompatibility, and low cytotoxicity when cocultured with human breast adenocarcinoma cells. Liposomes could traverse cell membranes and entered the central nervous system and neurocytes through the blood-spinal cord and blood-brain barriers of rats via the systemic circulation. These results verified that fluorescein isothiocyanate-modified transactivating-transduction protein-polyethylene glycol liposomes have the ability to traverse the blood-spinal cord and blood-brain barriers.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2012年第35期2784-2792,共9页 中国神经再生研究(英文版)
基金 sponsored by grants from the National Natural Science Foundation of China,No.30872603 the New Century Excellent Talents Program of the Ministry of Education of China,No.NCET-06-0251 the Applied Basic Research Programs of Science and Technology Commission Foundation of Tianjin,China,No.07JCYBJC10200
关键词 liposomes transactivating-transduction protein polyethylene glycol blood-spinal cord barrier blood-brain barrier caudal vein fiuorescein isothiocyanate rat human breast adenocarcinomacells (MCF-7) cytobiology neural regeneration liposomes transactivating-transduction protein polyethylene glycol blood-spinal cord barrier blood-brain barrier caudal vein fiuorescein isothiocyanate rat human breast adenocarcinomacells (MCF-7) cytobiology neural regeneration
  • 相关文献

参考文献1

二级参考文献27

  • 1董炎明,阮永红,赵雅青,毕丹霞,杨柳林,葛强.N-烷基壳聚糖玻璃化转变温度的研究[J].物理化学学报,2005,21(11):1307-1310. 被引量:5
  • 2Muzzarelli, R, A. A.; Ilari, P. Int. J. Biol. Macrom., 1994, 16:177.
  • 3Sieval, A. B.; Thanou, M.; Kotze, A. F.; Verhoef, A. F.; Brussee, J.; Junginger, H. E. Carbohydr. Polym., 1998, 36:157.
  • 4Thanou, M.; Florea, B, I.; Geldof, M.; Junginger, H. E.; Borchard, G. Biomaterials, 2002, 23:153.
  • 5Lim, S. H; Hudson, S. M. Carbohydrate Research, 2004, 339:313.
  • 6Jia, Z. S.; Shen, D. F.; Xu, W. L. Carbohydrate Research, 2001, 333:1.
  • 7Thanou, M.; Florea, B. I.; Langemeyer, M. W. E.; Verhoef, J. C.; Junginger, H, E. Pharm. Res., 2000, 17:27.
  • 8Thanou, M.; Verhoef, J. C.; Verheijden, J. H. M.; Junginger, H. E. Pharm. Res., 2001, 18:823.
  • 9Kotze, A. F.; Thanou, M. M.; Luexen, H. L.; Boer, B. G.; Verhoef, J. C.; Junginger, H. E. Eur. J. Pharm Biopharm., 1999, 47:269.
  • 10Lukyanov, A. N.; Torchilin, V. P. Adv. Drug Deliv. Rev., 2004, 56:1273.

共引文献17

同被引文献3

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部